[1] 景楚瑜. 抗PD-1/PD-L1治疗在肿瘤治疗中的研究进展.复旦学报(医学版),2016,43:710-716.
[2] 包晓燕,陈飞,金铁峰,等. PD-1/PD-L1抑制剂在晚期NSCLC免疫治疗中的应用研究进展.浙江医学,2019,41:202-206.
[3] 祁玲,黄镜. PD-1/PD-L1抑制剂在晚期胃癌治疗中的临床研究进展.中国生化药物杂志,2016,12:4-7.
[4] 王征帆,王豪勋,李楠,等. 原发性肝癌PD-L1和PD-L2表达. 医药论坛杂志, 2016,12:4-7.
[5] 张再兴,周尚清. PD-1、PD-L1在喉癌中的表达及临床意义.重庆医学,2018,47:635-637.
[6] 王立东,徐卫国,杨鑫,等. PD-L1在乳腺癌中的表达及其与细胞免疫的相关性分析.重庆医学,2018,47:1207-1209.
[7] 谢丽叶, 付杰军, 卢奕,等. PD1/PD-L1激活促进癌症发生、发展和转移的研究进展. 肿瘤防治研究, 2017, 44:423-427.
[8] Kakavand H, Wilmott J S, Menzies A M, et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clin Cancer Res, 2015, 21:3140-3148.
[9] Colette DD, Isabelle D, Laurent A, et al. A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. Oncoimmunology, 2016, 5:142- 143.
[10] Liu Y X, Wang X S, Wang Y F, et al. Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis. Onco Targets Ther, 2016, 9:2649-2654. |
